Remember the promise that hair loss would one day be solved by "reactivating" dead-looking follicles instead of just slowing the decline? Yeah — that idea has been floating around for years. PP405 is one of the first real attempts to test it in humans.
This is the most mechanistically different thing on our pipeline tracker, so it's worth understanding — even though it's early.
What PP405 is
PP405, from Pelage Pharmaceuticals (spun out of UCLA research), is an experimental topical drug for androgenetic alopecia. It doesn't touch DHT, and it isn't minoxidil. It goes after something upstream: the metabolism of the follicle's own stem cells.
How it works (the genuinely new part)
Here's the concept, in plain terms. Hair follicles have stem cells that cycle between resting and producing hair. In pattern hair loss, more and more of them get stuck in a dormant state.
PP405 targets a metabolic switch called the mitochondrial pyruvate carrier (MPC). Block that carrier, and the stem cells shift how they burn fuel (toward glycolysis) — a change that appears to nudge dormant follicles back into an active, growing state. [1][2]
Think of it like this. Minoxidil and finasteride manage the conditions around the follicle — blood flow, hormones. PP405 is trying to flip a switch inside the follicle's own stem cells to wake them up. Different target, different layer of the problem.
What the trials actually show
PP405 reported Phase 2a data, and the early signal was encouraging: roughly 31% of participants achieved more than a 20% increase in hair density at 8 weeks, versus 0% on placebo, with signs of stem-cell activation detectable after just one week of treatment. It's reported as non-hormonal, with no systemic absorption observed. [1][2]
Now, the mandatory reality check from how we read trial results:
- This is Phase 2a — small and early. "31% saw a density bump at 8 weeks" is a promising signal, not proof of durable, cosmetically meaningful regrowth.
- 8 weeks is short. AGA plays out over months to years. Early density changes need to hold up over much longer follow-up.
- A novel mechanism cuts both ways: exciting upside, but also less long-term human safety history than decades-old drugs. Larger, longer trials (Phase 3) are what matter next, and those are the ones to watch. [2]
Bottom line on the data: one of the most exciting mechanisms in the pipeline, with a real (if early) human signal — but firmly investigational, and years from any pharmacy shelf if it succeeds at all.
Realistic expectations
- PP405 is not available, and won't be for some time even in the best case.
- If it works out, its appeal is being non-hormonal and mechanism-novel — potentially attractive to people who can't or won't use DHT-based drugs, and complementary to existing treatments rather than a replacement.
- Treat the "regrow dormant follicles" framing with healthy skepticism until Phase 3 data lands. The graveyard of hair-loss history is full of Phase 2 excitement that didn't hold.
How I'd think about it
I try to hold two things at once with something like PP405: real enthusiasm for a fresh mechanism, and discipline about early-stage data. What I won't do is reorganize my regimen around a drug that's years away and might not pan out. What I will do is keep this page updated and keep my own baseline photos current in the tracker — so that if PP405 (or anything like it) becomes real, I've got a clean before-picture to measure it against. That's the practical move: stay informed, stay measured, don't chase headlines.
FAQ
Is PP405 available to buy? No. It's an investigational drug in early clinical trials (Phase 2a reported), not approved or for sale. Beware anyone claiming to sell "PP405." [1]
How is PP405 different from minoxidil or finasteride? Completely different target. Minoxidil stimulates growth and finasteride lowers DHT; PP405 acts on follicle stem-cell metabolism (the MPC) to try to reactivate dormant follicles. It's non-hormonal. [1][2]
When could PP405 be available? Unknown — it still needs to succeed in larger, longer (Phase 3) trials before any FDA review. Even in a best case that's years out. We update this page as its status changes.
Sources
- Dermatology Times — Pelage's PP405 Demonstrates Efficacy in Phase 2a Trial for Androgenetic Alopecia. https://www.dermatologytimes.com/view/pelage-s-pp405-demonstrates-efficacy-in-phase-2a-trial-for-androgenetic-alopecia
- Pelage Pharmaceuticals clinical program overview / Phase 2a reporting (verify latest company release before republishing).
Investigational drug; not medical advice. See our editorial standards and medical disclaimer. Add the primary Phase 2a citation and refresh on Phase 3 news.